{"schema_version":"secwatch.filing_event.v1","accession":"0001965040-23-000048","form_type":"8-K","ticker":"FTRE","cik":"0001965040","company_name":"Fortrea Holdings Inc.","filed_at":"2023-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.469982+00:00","generated_at":"2026-06-07T20:33:37.034083+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fortrea disputes ACELYRIN claims on HS and PsA trial conduct; stands by data integrity","bullets":["Fortrea objects to ACELYRIN's implication that its conduct of the Hidradenitis Suppurativa trial impacted outcomes.","Disputes accuracy of statements about testing processes and who uncovered the third-party programming error in Psoriatic Arthritis trial.","Sequencing issue isolated to two arms of the PsA trial, unrelated to the HS trial; no patient safety risk per ACELYRIN.","Third-party programmer not endpoint Clinical (affiliated with Fortrea); cannot be named due to contractual commitments."],"urls":{"canonical":"https://secwatch.observer/filing/0001965040-23-000048","json":"https://secwatch.observer/filing/0001965040-23-000048.json","markdown":"https://secwatch.observer/filing/0001965040-23-000048.md","text":"https://secwatch.observer/filing/0001965040-23-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1965040/000196504023000048/0001965040-23-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1965040/000196504023000048/ftre-20231127.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T20:33:37.034083+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}